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C
raniosynostosis, the premature fusion of one or more
sutures of the skull, is a common craniofacial anomaly,
with an estimated incidence of 1/2000 to 1/3000
births.1 2 Characteristic deformities of skull shape occur as a
result of different patterns of sutural fusion, while compen-
satory skull expansion occurs at unaffected sutures to
accommodate the growing brain. Premature fusion of the
sagittal suture, for example, results in anterior to posterior
elongation of the skull known as scaphocephaly.2 Sagittal
synostosis is the most common type of craniosynostosis,
occurring in 40–58% of cases reported in large neurosurgical
surveys, and shows a male predominance.3–6 Most of the
cases in these reports are ‘‘non-syndromic’’ instances of
sagittal synostosis, while familial cases represent 2–9% of the
total. Mental retardation is uncommon in isolated sagittal
synostosis, but is more common in cases with associated
malformations.4–6 Over 90 syndromic forms of craniosyno-
stosis have been described. Apert, Crouzon, Pfeiffer, Muenke,
and Saethre–Chotzen syndromes are the most common of
these, being classified according to the clinical involvement of
the cranium, face, hands and feet, and other organs.2 In these
syndromes, brachycephaly or acrocephaly resulting from
coronal synostosis is the predominant cranial deformity,
and this is variably associated with mid-face hypoplasia,
broad toes, syndactyly, and intellectual deficits. Sagittal
synostosis is seen almost exclusively in combination with
coronal synostosis,2 while macrocephaly in the absence of
craniosynostosis occurs infrequently.7 Familial scaphocephaly
syndromes, which include Berant syndrome, ‘‘Philadelphia’’
type craniosynostosis, and Jones craniosynostosis,2 are rare
and their molecular aetiology remains unknown.
Mutations in five genes have been shown to cause various
craniosynostosis syndromes. These are the transcription
factor genes TWIST (Saethre–Chotzen syndrome, MIM
101400) and MSX2 (Boston-type craniosynostosis, MIM
604757), and three fibroblast growth factor receptor genes,
FGFR1, FGFR2, and FGFR3 (Pfeiffer syndrome, MIM 101600;
Apert syndrome MIM 101200; Crouzon syndrome, MIM
123500; Jackson–Weiss syndrome, MIM 123500).1 Mutations
in TWIST, FGFR2, and FGFR3 also cause isolated non-
syndromic coronal synostosis8; however, mutations resulting
in isolated sagittal suture synostosis and scaphocephaly have
yet to be identified. The FGFR mutations have been located
predominantly in hotspots in these genes in the more than
800 patients where mutations have been characterised.1 9
Only one FGFR1 mutation, P252R, has been identified and it
results in a mild Pfeiffer syndrome variant.10 In contrast,
FGFR2 mutations are a common cause of several craniosy-
nostosis syndromes: Pfeiffer, Apert, Crouzon, Jackson–Weiss,
and Beare–Stevenson (MIM 123790).1 11 The FGFR2 muta-
tions are non-randomly distributed throughout the gene,
concentrated in exons 8 and 10. Two mutations, S252W and
P253R, are relatively common and invariably cause Apert
syndrome.1 11 In FGFR3, the A391E mutation causes Crouzon
syndrome with acanthosis nigricans and the P250R mutation
causes Muenke syndrome (MIM 602849). Mutations in
FGFR3 also cause thanatophoric dysplasia (MIM 187600).
Although craniosynostosis is a feature of this disorder, it is
more commonly considered a severe generalised skeletal
dysplasia.11 12 FGFR3 mutations also result in a range of other
chondrodysplasias including achrondroplasia and hypochon-
droplasia, emphasising the central role that FGF signalling
plays in skeletal development.12 The wide range of limb
abnormalities that occurs in the craniosynostosis syndromes
indicates that the pathways of cranial bone growth and
limb morphogenesis share some critical components.
Characterisation of the genes involved in these syndromes
is providing important information about the regulatory
pathways of craniofacial and skeletal development.
We report the clinical and molecular findings in a three
generation family showing autosomal dominant inheritance
of a novel craniosynostosis syndrome (fig 1). Thirty family
members were examined and the clinical findings are
detailed in table 1. The appearances of the 11 affected
individuals are shown in fig 2. The study was approved by the
Royal Children’s Hospital ethics in human research commit-
tee, and informed consent was obtained from participating
family members. All the subjects shown in fig 2, or their legal
guardians, gave written consent for their images to be
reproduced in this paper. Macrocephaly was defined as an
occipito-frontal circumference greater than the 98th centile
Key points
N A large family is reported in which three generations
show dominant inheritance of a new craniosynostosis
syndrome characterised by scaphocephaly, macroce-
phaly, severe maxillary retrusion, and mild intellectual
disability.
N Molecular analysis revealed a novel K526E mutation in
the TK1 portion of the intracellular split tyrosine kinase
domain of the fibroblast growth factor receptor 2 gene
(FGFR2). The mutation is located at the cleft between
the TK1 and TK2 lobes of the domain and is predicted
to stabilise the activation loop in an active conforma-
tion.
N This is the first report of a mutation causing a familial
scaphocephaly syndrome with almost exclusive invol-
vement of the sagittal suture. These data indicate that
FGFR2 mutations are responsible for an extended
range of phenotypes, which might include isolated
sagittal synostosis; they underline the importance of
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for age.13 Hypertelorism was defined as an interpupillary
distance greater than the 97th centile for age.14 Intellectual
disability was determined by formal neuropsychological
testing in individual IV:11 (Wechsler intelligence scale for
children), and by paediatric assessment of individuals IV:2
and IV:31. Individual III:3 did not succeed at mainstream
schooling and at 36 years of age was unable to live
independently. He was thus considered to have an intellec-
tual disability. Learning difficulty in other individuals was
based on family reporting of schooling difficulties. Statistical
analysis of the relation between genotype and learning
difficulties was carried out using Pearson’s x2 test.
The 11 affected individuals have varying degrees of
craniofacial dysmorphism (fig 1, table 1). Seven (63%) have
scaphocephaly and 10 (91%) have macrocephaly. Of 19
unaffected individuals, three had macrocephaly with tall
stature, and none had scaphocephaly. More severely affected
individuals (for example, IV:11 and III:3) are male and have
scaphocephaly, macrocephaly, a high forehead, marked mid-
face hypoplasia with severe maxillary retrusion, relative or
absolute prognathism, and class III malocclusion. This results
in a ‘‘scooped out’’ or concave profile. More severely affected
individuals have intellectual disability in the borderline to
mild range.
Proband IV:11 presented aged four years with scaphoce-
phaly, macrocephaly, and severe maxillary retrusion, and he
has ‘‘borderline’’ intellectual ability (WISC-III). Sagittal
synostosis was confirmed radiologically. He had surgery at
10 and 15 years of age (Le Forte III and maxillary distraction
osteotomy, respectively) to advance his midface, improve his
dental occlusion, and for cosmetic reasons.
The only other family member who underwent cranio-
facial surgery was individual IV:31. He had congenital
trigonocephaly from metopic synostosis, congenital macro-
cephaly with macrosomia, broad and medially deviated great
toes, complete soft tissue syndactyly of the second and third
toes, mild ‘‘dysplastic’’ cerebral ventriculomegaly, and mild
developmental delay. He had a bilateral surgical fronto-
orbital advancement to correct the metopic synostosis at
eight months for cosmetic reasons. His mother (III:24) has a
broad great toe and partial 2,3 syndactyly of the toes.
Radiographs of the feet of IV:31 and III:24 confirmed the
clinical findings, but did not show bony fusion.
Aside from IV:31 and III:24, none of the family members
had significant feet findings on examination, and none had
hand abnormalities. Mildly affected individuals (for example,
II:2) have macrocephaly with a high forehead and mild
maxillary retrusion. Hypertelorism appeared to be propor-
tional to the macrocephaly. Affected individuals have
variable stature ranging from the 3rd to above than the
97th centile for age.
The clinical presentation of this family thus appears
distinct from other known craniosynostosis syndromes.








Individuals who underwent detailed clinical examination





15 1712 18 19
1
V
2524 2726 3129 30282322212016109 1184 765321
2
Figure 1 Pedigree of the family affected with a novel scaphocephaly syndrome.
Table 1 Summary of clinical findings in 11 affected family members
Characteristic II:2 II:5 III:2 III:3 III:12 III:24 IV:2 IV:3 IV:11 IV:28 IV:31
Scaphocephaly – + – + – + + + + + –*
Macrocephaly + + + + + + – + + + +
Head circumference 58.5 63.5 61 63 59 58 56 57.8 59 60 55.5
98th centile 57.6 58.2 58.2 58.2 57.6 57.6 57.2 57.2 57.8 56.2 52.5
High forehead + – + – + + + + + + +
Hypertelorism` – + + + + + + + + + +
Maxillary retrusion + + + + + + + + + + +
Malocclusion – + – + + – – + + + +
Prognathism1 – – + + + – – – – – –
High arched palate + – + – + – + + + – +
Syndactyly – – – – – + – – – + ++
Broad great toe – – – – – + – – – – +
Learning difficulty** – + + ++ – – ++ + ++ + ++
*Trigonocephaly.
Head circumference in cm; standard head circumference and percentile values are those described in reference 13.
`Proportional to macrocephaly.
1Absolute prognathism.
2,3 Soft tissue toe syndactyly; +, partial; ++, complete.
**+, family reporting schooling difficulties; ++, borderline or mild intellectual disability or developmental delay on clinical assessment (see text).
ND, not determined; +, present; –, absent.
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Figure 2 Appearances of affected family members. Photographs of the 11 affected family members are shown. Lateral photographs of individuals
IV:11, II:5 and III:3 show the ‘‘scooped out’’ profile resulting from the severe maxillary retrusion. The three dimensional craniofacial computed
tomography scans of individual IV:11 show the patent coronal and lamboid sutures, and the complete obliteration of the sagittal suture. Individual
IV:31 is shown before and after craniofacial surgery and the photograph of his feet illustrates the complete 2,3 soft tissue toe syndactyly and the broad
great toe. Written consent was obtained from patients or legal guardians for publication of these clinical photographs.
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been reported in Crouzon syndrome in a small percentage of
cases, and usually in combination with lambdoid synostosis.2
The absence of shallow orbits and ocular proptosis in
members of this kindred excludes Crouzon syndrome.
Similarly, Pfeiffer syndrome is distinguished by the presence
of broad thumbs, and this feature was not present in any
affected family members.
A significant proportion of affected individuals had a
history of learning difficulties when compared with unaf-
fected family members (x2=9.7, p=0.002). This difference
remained significant after exclusion of the propositi. Mild
intellectual disability was associated with a more severe
craniofacial phenotype in III:3, IV:2, IV:11, and IV:31. The
absence of intracranial hypertension in scaphocephalic family
members and the associated facial malformation indicates
that intellectual impairment might be a primary consequence
of the gene mutation rather than a secondary effect related to
timing of surgery.
Initially, we screened for mutations in the genes known to
be associated with craniosynostosis. The FGFR1 P252R
mutation found in mild Pfeiffer syndrome, and the Muenke
syndrome FGFR3 P250R mutation1 were not detected in
patient IV:11 by diagnostic restriction enzyme digestion of
genomic polymerase chain reaction (PCR) products. The
FGFR2mutation hot spots in exons 8, 10, and 11 identified in
Apert, Crouzon, Pfeiffer, and Beare–Stevenson syndromes,1 9
and the single coding exon of TWIST which contains
mutations in Saethre–Chotzen syndrome patients,1 were
screened by denaturing high performance liquid chromato-
graphy (DHPLC) and gene sequencing. No mutations were
found. An activating mutation in the homeobox gene MSX2
causes dominantly inherited Boston-type craniosynostosis15
and so we directly sequenced the two exons of MSX2. We also
sequenced the ALX4 gene, haploinsufficiency of which results
in parietal foramina.16 No mutations were found in either of
these genes.
While most of the characterised FGFR2 mutations are
located in exons 8 and 10 which code for the third
extracellular immunoglobulin-like domain (IgIII), or in exon
11 which encodes the transmembrane domain, a recent
complete FGFR2 mutation screen identified mutations in six
additional exons—3, 5, 14, 15, 16, and 17.9 We therefore
screened these exons by DHPLC of genomic PCR products
and direct sequencing.
A heterozygous base change, c.1576ARG, was identified in
exon 14 of FGFR2 in patient IV:11 (fig 3A). This is a novel
change that results in a non-conservative amino acid
substitution, K526E, within the intracellular TK1 domain
(fig 3B). The base change creates a new MboII restriction
enzyme recognition site that allowed the development of a
diagnostic restriction enzyme assay to track the change in
affected and unaffected family members and controls
(fig 3C). The change was found in all 11 affected individuals
but not in the 19 unaffected family members who were
examined, nor in 110 control chromosomes (data not
shown), indicating that FGFR2 K526E is not a common
polymorphism and is likely to be the pathogenic mutation in
this family. Consistent with this, a lysine residue is found in
Figure 3 A mutation in the FGFR2 tyrosine kinase domain. (A) A
heterozygous ARG substitution in FGFR2 exon 14 that resulted in a
K526E amino acid substitution was identified in affected family members
(lower chromatogram). Protein translations of the first eight complete
codons of exon 14 are shown below the chromatogram. This mutation
was not present in unaffected family members or controls (upper
chromatogram). (B) The novel K526E mutation (arrow) is in the TK1
portion of the split tyrosine kinase domain. The FGFR2 extracellular
immunoglobulin-like domains, IgI, IgII, and IgIII are shown, and the cell
membrane is indicated by the two vertical lines. The intracellular split
tyrosine kinase domain (TK1 and TK2) is indicated by the two boxes. (C)
The presence of the mutation was tracked by restriction enzyme digestion
(MboII) of genomic polymerase chain reaction products from 30 family
members. The analysis of six family members is shown. Wild-type
genotypes resulted in fragments of 123, 113, and 13 bp (individuals
IV:27, IV:29, and IV:30). The 123 and 113 bp bands were not resolved
and the 13 bp band is too small to see. Carriers of the mutation have
bands of 113, 85, 38, and 13 bp (individuals III:24, IV:28, and IV:31).
Eleven affected individuals carried the mutation and it was not present in
19 unaffected family members or in 110 control chromosomes.
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the 526 position, or its equivalent, in all FGFR proteins,
suggesting that it plays a crucial role in FGFR tyrosine kinase
domain function. This is the first report of a pathogenic
mutation in a craniosynostosis syndrome manifesting pre-
dominantly as scaphocephaly.
To assess the potential pathogenic significance of the
mutation we produced structural models of the wild-type
(K526) and mutant E526 FGFR2 tyrosine kinase domain
(fig 4). The models were based on coordinates from the
publicly available crystal structures of the FGFR117 (PDB
1FGI) and FGFR2 (PDB 1GJO) tyrosine kinase domains. The
models were produced using the program MODELLER, and
refined by conjugate gradient energy minimisation and
simulated annealing in explicit water using the program
NAMD.18–20 All modelling was carried out on the super-
computing facilities at the South Australian Partnership for
Advanced Computing (Adelaide, South Australia). Structural
comparison with the published structures of the kinase
domains from FGFR1,17 insulin receptor (IRK), and the
activated insulin receptor (IRK3P)21 confirms that K526 of
the wild-type FGFR2 is located in the aC helix at the interface
between the N-terminal ATP binding lobe and the C-terminal
Figure 4 Comparison of the insulin receptor and FGFR2 tyrosine kinase domains. (A) Superimposition of the ribbon diagrams of the insulin receptor
tyrosine kinase domain (IRK) coloured light grey, and the activated form of the insulin receptor tyrosine kinase (IRK3P) coloured dark grey, is shown on
the left. The aC helix and the activation loop (A loop) of IRK is shown in red and the aC helix and A loop of IRK3P is shown in green. Superimposition of
the homology model of the wild-type FGFR2 tyrosine kinase domain (FGFR2 K526, light grey) and the K526E mutant tyrosine kinase (FGFR2 E526,
dark grey) is shown on the right. The aC helix and the activation loop (A loop) of the wild-type tyrosine kinase, K526, is shown in red and the aC helix
and A loop of the mutant, E526, is shown in green. The conformation of the A loop of the mutant E526 tyrosine kinase resembles the active state seen
in IRK3P. (B) The aC helix and activation loop of the inactive wild-type FGFR2 (left) and mutant FGFR2 E526 tyrosine kinase (right). The representations
are taken from the superimposed ribbon diagram in (A) and equivalently rotated to more clearly show key interacting residues from the aC helix and
A loop. In the wild-type, K526 forms a salt bridge with D530; however, in the mutant the substituted E526 residue and D530 both interact with R664,
thereby stabilising the A loop of FGFR2 in an active conformation. The carbon atoms of these residues are indicated in white, oxygen atoms in red, and
nitrogen atoms in blue. The hydrogen bond between E534 and the backbone amide hydrogen of F645 is the only other example of bonding between
the aC helix and the activation loop. Hydrogens are not shown. The figures were prepared with MOLSCRIPT.22
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substrate binding/catalytic lobe and forms a salt bridge with
the adjacent aspartate residue at position 530 (fig 4). Notably,
in the model generated for the K526E mutant, the
substituted E526 residue and D530 both interact with R664,
thereby stabilising the activation loop (A loop) of FGFR2
in an active conformation (fig. 4). Activation of tyrosine
kinase domains is accomplished by the ligand dependent
autophosphorylation of tyrosine residues in the A loop. This
phosphorylation results in a dramatic conformational change
in the A loop that permits the binding of ATP and substrate
peptide (fig 4A).21 Our mutant model predicts that the E526
mutation results in stabilisation of the active conformation of
the A loop of the FGFR2 tyrosine kinase domain that
probably occurs in the absence of activating ligand. This
predicted ligand independent activation will require experi-
mental confirmation.
Six mutations have previously been identified in the
intracellular tyrosine kinase domain of FGFR2.9 Like the
K526E mutation described here, all these mutations were
located in the cleft between the TK1 and TK2 domains and
are thought to activate the tyrosine kinase domain. Two of
the mutations K659N and N549H are located at conserved
residues equivalent to residues of FGFR3 at which mutations
have been experimentally shown to be activating.23 24 The six
previous FGFR2 tyrosine kinase domain mutations were
identified in patients with syndromic craniosynostosis.
Where phenotype data were present, all had either Crouzon
syndrome or Pfeiffer syndrome. Some patients had broad
thumbs and great toes, and developmental delay was
overrepresented compared with typical Crouzon and Pfeiffer
syndromes.9 One patient in this group, heterozygous for a
K641R mutation, had sagittal suture synostosis and scapho-
cephaly similar to the family described here, but also had
broad thumbs with radial angulation and a facial appearance
consistent with Pfeiffer syndrome. In contrast, two other
Pfeiffer syndrome patients who also carried the K641R
mutation did not have scaphocephaly, emphasising the
phenotypic variability that is common in craniosynostosis
syndromes. There does not appear to be a set of clinical
features that uniformly distinguishes patients with FGFR2
intracellular tyrosine kinase mutations from those with
mutations in the extracellular region. The current study
highlights the importance of extending FGFR mutation
screening beyond the exon 8 and 10 hotspots. This is
particularly important in patients and families with atypical
craniosynostosis syndromes. The presence of mutations in
the intracellular domains of FGFR2 should also be considered
when sagittal synostosis is found in association with changes
in midface development. The significance of FGFR2 muta-
tions in isolated sagittal synostosis should be further
assessed.
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Areas for which we are currently seeking authors:
N Child health: nocturnal enuresis
N Eye disorders: bacterial conjunctivitis
N Male health: prostate cancer (metastatic)
N Women’s health: pre-menstrual syndrome; pyelonephritis in non-pregnant women
However, we are always looking for others, so do not let this list discourage you.
Being a contributor involves:
N Selecting from a validated, screened search (performed by in-house Information
Specialists) epidemiologically sound studies for inclusion.
N Documenting your decisions about which studies to include on an inclusion and exclusion
form, which we keep on file.
N Writing the text to a highly structured template (about 1500–3000 words), using evidence
from the final studies chosen, within 8–10 weeks of receiving the literature search.
N Working with Clinical Evidence editors to ensure that the final text meets epidemiological
and style standards.
N Updating the text every six months using any new, sound evidence that becomes available.
The Clinical Evidence in-house team will conduct the searches for contributors; your task is
simply to filter out high quality studies and incorporate them in the existing text.
N To expand the topic to include a new question about once every 12–18 months.
If you would like to become a contributor for Clinical Evidence or require more information
about what this involves please send your contact details and a copy of your CV, clearly
stating the clinical area you are interested in, to Klara Brunnhuber (kbrunnhuber@
bmjgroup.com).
Call for peer reviewers
Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an
interest in the clinical areas stated above, and also others related to general practice. Peer
reviewers are healthcare professionals or epidemiologists with experience in evidence-based
medicine. As a peer reviewer you would be asked for your views on the clinical relevance,
validity, and accessibility of specific topics within the journal, and their usefulness to the
intended audience (international generalists and healthcare professionals, possibly with
limited statistical knowledge). Topics are usually 1500–3000 words in length and we would
ask you to review between 2–5 topics per year. The peer review process takes place
throughout the year, and our turnaround time for each review is ideally 10–14 days.
If you are interested in becoming a peer reviewer for Clinical Evidence, please
complete the peer review questionnaire at www.clinicalevidence.com or contact Klara
Brunnhuber (kbrunnhuber@bmjgroup.com).
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